Galmed Pharma Files 6-K with Q2 2025 Financials

TL;DR

Galmed Pharma dropped its Q2 2025 financials, check the balance sheet for the latest numbers.

AI Summary

Galmed Pharmaceuticals Ltd. filed a 6-K report on August 28, 2025, detailing financial information for the period ending June 30, 2025. The filing includes balance sheet data for common stock, additional paid-in capital, accumulated other comprehensive income, and retained earnings as of various dates in 2023, 2024, and 2025. It also provides interim financial data for the first and second quarters of 2025 and 2024.

Why It Matters

This filing provides investors with an update on Galmed Pharmaceuticals' financial position and performance, crucial for evaluating the company's stability and investment potential.

Risk Assessment

Risk Level: low — This is a routine financial filing (6-K) providing standard financial data and does not indicate any unusual events or risks.

Key Numbers

• Q2 2025 — Financial Period (The filing provides financial data for this period.)
• 20250828 — Filing Date (The date the report was submitted to the SEC.)

Key Players & Entities

• Galmed Pharmaceuticals Ltd. (company) — Filer of the report
• 20250828 (date) — Filing date
• 20250630 (date) — Period of report

FAQ

Key Financial Figures

• $ — K, "NIS" means New Israeli Shekel, and "$," "US$" and "U.S. dollars" mean United
• $2 m — capital through an investment of up to $2 million, subject to execution of definiti
• $204.1 million — an accumulated deficit of approximately $204.1 million. Our financing activities are describ

Filing Documents

• form6-k.htm (6-K) — 433KB
• ex99-1.htm (EX-99.1) — 76KB
• 0001493152-25-012420.txt ( ) — 1990KB
• glmd-20250630.xsd (EX-101.SCH) — 13KB
• glmd-20250630_cal.xml (EX-101.CAL) — 28KB
• glmd-20250630_def.xml (EX-101.DEF) — 39KB
• glmd-20250630_lab.xml (EX-101.LAB) — 145KB
• glmd-20250630_pre.xml (EX-101.PRE) — 101KB
• form6-k_htm.xml (XML) — 167KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2025 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Abba Hillel Road , Ramat Gan , Israel 5250608 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K contains the quarterly report of Galmed Pharmaceuticals Ltd. (the "Company"), which includes the Company's unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2025, together with related information and certain other information. The Company is not subject to the requirements to file quarterly or certain other reports under Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company does not undertake to file or cause to be filed any such reports in the future, except to the extent required by law. On August 28, 2025, the Company issued a press release announcing the filing of its financial results for the three and six months ended June 30, 2025, with the Securities and Exchange Commission. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. This Form 6-K is incorporated by reference into the Company's Registration Statement on Form S-8 (Registration Nos. 333-206292 , 333-227441 and 333-284163 ) and the Company's Registration Statements on Form F-3 (Registration Nos. 333-272722 and 333-283241 ). FINANCIAL INFORMATION Financial GALMED PHARMACEUTICALS LTD. Interim Condensed Consolidated Balance Sheets (Unaudited) U.S. Dollars in thousands, except share data and per share data As of As of June 30, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents $ 4,964 $ 4,652 Short-term deposit 7,464 3,496 Restricted Cash 123 121 Marketable debt securities 8,100 7,183 Other receivables 433 672 Total current assets 21,084 16,124 Investment in associate at fair value 1,593 2,119 Loan to associate 267 257 Total non-current assets 1,860 2,376 Total assets $ 22,944 $ 18,500 Liabilities and stockholders' equity Current liabilities Trade payables $ 1,369 $ 1,308 Other payables 1,052 865 Total current liabilities 2,421 2,173 Stockholders' equity Ordinary shares par value NIS 1.80 per share; Authorized 50,000,000 ; Issued and outstanding: 5,303,050 shares as of June 30, 2025 and 1,664,884 shares as of December 31, 2024 2,690 742 Additional paid-in capital 222,304 216,470 Accumulated other comprehensive loss ( 403 ) ( 416 ) Accumulated deficit ( 204,068 ) ( 200,469 ) Total stockholders' equity 20,523 16,327 Total liabilities and stockholders' equity $ 22,944 $ 18,500 The accompanying notes are an integral part of the interim condensed consolidated financial statements. GALMED PHARMACEUTICALS LTD. Interim Condensed Consolidated Statements of Operations (Unaudited) U.S. Dollars in thousands, except share data and per share data 2025 2024 2025 2024 Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Research and development expenses 1,058 534 1,692 1,169 General and administrative expenses 1,051 688 1,681 1,454 Total operating expenses 2,109 1,222 3,373 2,623 Financial income, net ( 140 ) ( 103 ) ( 300 ) ( 229 ) Impairment of Associate 526 - 526 - Net loss $ 2,495 $ 1,119 $ 3,599 $ 2,394 Basic and diluted net loss per share $ 0.63 $ 1.65 $ 1.25 $ 3.72 Weighted-average number of shares outstanding used in computing basic and diluted net loss per share 3,948,190 (*) 677,861 2,866,600 (*) 643,167 The accompanying notes are an integral part of the interim condensed consolidated financial statements. (*) Retroactively adjusted (See Note 3.1) GALMED PHARMACEUTICALS LTD. Interim Condensed Consolidated Statements of Comprehensive Loss (Unaudited) U.S. Dollars in thousands 2025 2024 2025 2024 Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Net loss $ 2,495 $ 1,119 $ 3,599 $ 2,394 Other comprehensive loss: Net unrealized loss (gain) on available for sale securities 6 ( 20 ) ( 13 ) ( 19 ) Comprehensive loss $ 2,501 $ 1,099 $ 3,586 $ 2,375 The accompanying notes are an integral part of the interim condensed consolidated financial statements. GALMED PHARMACEUTICALS LTD. Consolidated U.S. Dollars in thousands, except share data and per share data Shares Amount capital loss Deficit Total Accumulated Additional other Ordinary shares paid-in Comprehensive Accumulated Shares Amount capital loss Deficit Total Balance - Decemb

View Full Filing

View this 6-K filing on SEC EDGAR